138 related articles for article (PubMed ID: 36952534)
1. A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
Hawarden A; Price M; Russell B; Wilson G; Farrelly L; Embleton-Thirsk A; Parmar M; Edmondson R
PLoS One; 2023; 18(3):e0281798. PubMed ID: 36952534
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
3. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C; Kulbe H; Dreher F; Taube ET; Chekerov R; Horst D; Hummel M; Kessler T; Pietzner K; Kassuhn W; Heitz F; Muallem MZ; Lang SM; Vergote I; Dorigo O; Lammert H; du Bois A; Angelotti T; Fotopoulou C; Sehouli J; Braicu EI
Gynecol Oncol; 2022 Aug; 166(2):334-343. PubMed ID: 35738917
[TBL] [Abstract][Full Text] [Related]
5. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
Manning-Geist B; Cathcart AM; Sullivan MW; Pelletier A; Cham S; Muto MG; Del Carmen M; Growdon WB; Sisodia RC; Berkowitz R; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1356-1362. PubMed ID: 34518239
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
8. Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
Kumar A; Sheedy S; Kim B; Suidan R; Sarasohn DM; Nikolovski I; Lakhman Y; McGree ME; Weaver AL; Chi D; Cliby WA
Gynecol Oncol; 2019 Jul; 154(1):72-76. PubMed ID: 31000471
[TBL] [Abstract][Full Text] [Related]
9. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
10. Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.
Heitz F; Kommoss S; Tourani R; Grandelis A; Uppendahl L; Aliferis C; Burges A; Wang C; Canzler U; Wang J; Belau A; Prader S; Hanker L; Ma S; Ataseven B; Hilpert F; Schneider S; Sehouli J; Kimmig R; Kurzeder C; Schmalfeldt B; Braicu EI; Harter P; Dowdy SC; Winterhoff BJ; Pfisterer J; du Bois A
Clin Cancer Res; 2020 Jan; 26(1):213-219. PubMed ID: 31527166
[TBL] [Abstract][Full Text] [Related]
11. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
12. Higher Level of Fatty Acid Synthase Enzyme Predicts Lower Rate of Completing Debulking Surgery in Epithelial Ovarian Cancer.
Winarno GNA; Hidayat Y; Soetopo S; Krisnadi SR; Tobing MDL; Rauf S
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2859-2863. PubMed ID: 33112541
[TBL] [Abstract][Full Text] [Related]
13. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
[TBL] [Abstract][Full Text] [Related]
14. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of preoperative inflammatory markers and serum CA 125 level for surgical outcome in Indonesian women with epithelial ovarian cancer.
Sastra WIG; Aditya PPK; Gradiyanto OE; Ketut S
Cancer Biomark; 2022; 34(1):123-129. PubMed ID: 34806598
[TBL] [Abstract][Full Text] [Related]
18. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
[TBL] [Abstract][Full Text] [Related]
19. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
20. Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer.
Fuso L; Ferrero A; Vietti E; Petracchini M; Mineccia M; Villa M; Menato G
Int J Gynecol Cancer; 2019 Mar; 29(3):599-604. PubMed ID: 30829578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
